KDM5B and neoplasm: Previous studies validated that HEXIM1, the tumor suppressor, can be regulated by the H3K4me3/2 demethylase KDM5B. Therefore, KDM5B is identified as a druggable target to inhibit the proliferation of cancer by upregulation the expression levels of HEXIM1 [65].